What Is Semax?
Semax is a synthetic heptapeptide developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences. It was originally designed as a stable analogue of the adrenocorticotropic hormone fragment ACTH(4-10) — a sequence known to influence cognitive function and nervous system repair — but engineered to resist rapid enzymatic degradation that limits natural ACTH fragments.
Unlike traditional stimulants that work by flooding the brain with dopamine or blocking reuptake, Semax operates through an entirely different mechanism: it directly promotes the production of neurotrophic factors — the proteins your brain uses to grow, repair, and strengthen neural connections. This makes it fundamentally different from anything in the stimulant or nootropic mainstream.
Semax has been approved in Russia and Ukraine as a prescription medication for stroke recovery, cognitive impairment, and optic nerve disease. It is classified as a research peptide in most Western countries and is not FDA-approved for human use.
Its appeal in the biohacking community stems from a combination of a remarkably clean side effect profile, genuine scientific literature supporting its effects, and a unique dual action as both a cognitive enhancer and a neuroprotectant — qualities rarely found together in a single compound.
Mechanism of Action
Semax's pharmacology is multifaceted, operating through several interconnected pathways simultaneously. Understanding these mechanisms helps explain why its cognitive effects feel qualitatively different from stimulants.
Melanocortin Receptor Activation: As an ACTH(4-7)PGP analogue, Semax binds to melanocortin receptors MC1R through MC5R. These G-protein coupled receptors are distributed throughout the central nervous system and are involved in mood regulation, nociception, inflammation, and cognitive processing. Activation of MC4R in particular appears central to Semax's nootropic effects.
BDNF Upregulation: Brain-Derived Neurotrophic Factor is perhaps the most critical protein for neuroplasticity and memory formation. Semax has been shown in multiple studies to produce rapid, significant increases in BDNF expression in the cortex and hippocampus — key regions for executive function and long-term memory. This upregulation occurs within hours of administration and persists beyond the compound's half-life, which partially explains why cognitive benefits can outlast the dosing window.
VEGF and NGF Effects: Semax also upregulates Vascular Endothelial Growth Factor (VEGF), improving cerebral microcirculation, and Nerve Growth Factor (NGF), which supports the survival and maintenance of cholinergic neurons critical to memory and attention.
Dopaminergic and Serotonergic Modulation: Research indicates Semax modulates both dopaminergic and serotonergic transmission in prefrontal and limbic circuits. This contributes to its anxiolytic properties and motivational enhancement without the receptor downregulation associated with direct agonists.
Key Benefits
BDNF Upregulation
Directly increases brain-derived neurotrophic factor — the protein responsible for neural growth, plasticity, and the formation of long-term memories.
Focus & Working Memory
Users consistently report significantly improved ability to hold and manipulate information in working memory, with cleaner focus than stimulants.
Neuroprotection
Studied extensively in stroke models. Semax reduces neuronal apoptosis, limits ischemic damage, and has demonstrated clinical benefit in post-stroke cognitive recovery.
Anxiety Reduction
Modulates serotonergic and GABAergic pathways to produce a calm, focused state — not the anxious edge associated with stimulants like caffeine or amphetamines.
Cognitive Restoration
Has shown particular promise in populations with cognitive deficits from injury, neurodegenerative conditions, or chronic stress. The neurotrophic mechanism targets restoration, not just short-term enhancement.
No Stimulant Crash
Because Semax does not act on monoamine reuptake or directly stimulate catecholamine release, there is no post-dose crash, no tolerance-driven dose escalation, and no rebound fatigue.
Dosing & Protocol
| Experience Level | Daily Dose | Timing | Frequency |
|---|---|---|---|
| Beginner | 200–300 mcg | Morning, fasted | Daily × 14 days |
| Intermediate | 300–600 mcg | Morning or split AM/Noon | Daily × 14 days |
| Advanced | 600–900 mcg | Split into 2–3 doses | Daily × 14 days |
Cycle Structure: The standard protocol is 2 weeks on, 1 week off. This cycling pattern helps prevent receptor adaptation and preserves the pronounced effects of each course. Some users run 3 weeks on with a 10-day break, especially when using lower doses.
Administration Technique: Tilt head slightly forward, insert spray nozzle into one nostril, spray while inhaling gently. Alternate nostrils. Avoid blowing nose for at least 5 minutes after dosing to allow mucosal absorption. Store refrigerated at 2–8°C.
Timing for Cognitive Tasks: Effects typically onset within 20–40 minutes of intranasal administration. For best results with demanding cognitive work, dose 30–45 minutes before the target task window.
Side Effects & Safety
Semax has one of the most favorable safety profiles among research peptides, consistent with its decades of clinical use in Eastern Europe. However, no compound is without risk, particularly in novel applications.
Rare but Reported: Allergic reactions to the peptide itself or preservatives in the formulation. If experiencing unusual itching, rash, or respiratory changes, discontinue and consult a physician.
Mood Considerations: A small subset of users report feeling slightly over-stimulated or irritable, particularly at doses above 600 mcg. This is typically resolved by reducing to a lower dose or splitting the daily amount across two administrations.
Long-Term Safety: While Semax has been used clinically in Russia for over 30 years with a strong safety record, long-term human data in the research peptide context (outside prescribed clinical use) remains limited. Annual breaks and conservative dosing are prudent.
Contraindications: Individuals with seizure disorders should exercise caution, as any compound that modulates neuronal excitability warrants careful monitoring. Pregnancy and breastfeeding are absolute contraindications in the absence of clinical oversight.
Stacking Guide
Semax synergizes well with several compounds, particularly those targeting complementary aspects of cognitive function.
Classic Cognitive Stack: Semax (300 mcg intranasal AM) + Selank (250 mcg intranasal PM or pre-sleep). This pairing provides BDNF elevation throughout the day while the Selank's anxiolytic and enkephalin-modulating properties add a calming, focused quality often described as "smooth productivity."
Do Not Combine With: Monoamine oxidase inhibitors (MAOIs) without medical supervision. Use caution combining with other peptides that also modulate BDNF until you understand your individual response to each compound separately.
Get Personalized Stacking Recommendations
Join SDBioHack free to access our stack builder, protocol database, and member community.
Frequently Asked Questions
Semax and stimulants like Adderall operate through completely different mechanisms. Adderall works by flooding synapses with dopamine and norepinephrine — creating an artificial state of high arousal that your brain compensates for over time, leading to tolerance, dependence, and the characteristic "crash." Semax, by contrast, works upstream: it tells your brain to produce more BDNF and modulates melanocortin receptors to improve neuroplasticity itself. The subjective experience is often described as "my brain working better" rather than "my brain being forced to work." There's no crash, no tolerance escalation, and no dependency. The tradeoff is that the effect is more subtle — you won't feel the immediate jolt of a stimulant, but the cognitive improvements tend to be more functional and sustainable.
Acute effects — primarily improved focus and clarity — typically manifest within 20–45 minutes of intranasal administration. However, the more profound effects, particularly improvements in memory consolidation and the cumulative BDNF upregulation, tend to become apparent over several days of consistent dosing. Many users describe a noticeable shift in cognitive baseline by days 3–5 of a cycle. The neurotrophic effects (BDNF elevation, potential synaptic remodeling) continue accumulating over the 14-day cycle and may persist for days to weeks after the cycle ends — this residual benefit is one of Semax's most distinctive characteristics.
The standard recommendation is to cycle Semax (2 weeks on, 1 week off) rather than using it continuously. This is based on two rationales: first, melanocortin receptor downregulation may blunt effects over time without breaks; second, the neurotrophic effects themselves appear to persist into the off-cycle period, meaning the break is not "wasted" — your brain continues integrating the BDNF-driven changes. Some advanced users run longer cycles (3–4 weeks) with proportionally longer breaks. Continuous indefinite daily use without cycling is not well-studied and is generally considered suboptimal both for efficacy and for an abundance of caution regarding long-term receptor dynamics.
Key References
- Dolotov OV, et al. "Semax, an analogue of ACTH(4-7), regulates BDNF and trkB expression in the rat hippocampus." Journal of Neurochemistry, 2006.
- Miasoedov NF, et al. "Semax and its Active Metabolite Pro-Gly-Pro Influence Nerve Growth Factor and Expression of Its Receptors." Neurochemistry International, 2018.
- Vasileva EV, et al. "Neuroprotective effects of Semax in focal ischemia: evidence from clinical trials." Stroke, 2001.
- Gusev EI, Skvortsova VI. "Brain ischemia." New York: Kluwer Academic/Plenum Publishers, 2003.